8 RESULTS
COMMENT I was extremely saddened to read that Peter Davies died recently. His pivotal and pioneering study published in Lancet with A.J. Maloney indicated the importance of cholinergic hypofunction in Alzheimer’s disease and provided the rationale for the ...
COMMENT The paper by Davis et al. adds further support to the major and pivotal role of the M1 muscarinic receptor (M1 AChR) in AD pathology and possible treatment with selective M1 agonists. It adds indirect support to our earlier findings that M1 agonists such ...
COMMENT This is a very interesting paper. It would be very important to know whether this receptor also mediates tau hyperphosphorylation as shown for the α7 nicotinic receptors in some, but not in all, papers that tested the correlation. I’d like to clarify that ...
COMMENT The difficulty in developing drugs for specific subtypes of some neurotransmitter receptors is that the transmitter binding site is normally highly conserved. One way around this is to design molecules that modulate a putative allosteric site(s) in the ...
COMMENT Reply by Abraham Fisher to Takaomi Saido In reply to Takaomi Saido’s questions: The progression of Alzheimer disease (AD), associated with loss of the cholinergic neurons and decreases in acetylcholine (ACh), limit the therapeutic potential of the FDA ...
COMMENT Conner et al. (2005) show in this elegant paper that the basal forebrain cholinergic system plays an essential role in cortical plasticity and functional recovery following brain injury. Thus, even partial cholinergic hypofunction may cause a disruption ...
COMMENT The authors report that acetylcholinesterase (AChE)-deficient mice have markedly decreased expression of muscarinic receptor (mAChR) subtypes (M1, M2 and M4) in brain regions associated with memory. This was accompanied by a robust decrease in mAChR ...
COMMENT Phiel et al. (2003) show that Lithium (Li), an inhibitor of GSK3β and GSK3α, can decrease Aβ via inhibition of γ-secretase and of GSK3α. These new findings indicate that inhibition of GSK3α is an important therapeutic target in Alzheimer’s disease (AD). ...
